Stereotactic Ablative Radiotherapy Delays Systemic Therapy Escalation in Oligoprogressive Renal Cell Carcinoma
Key Clinical Takeaways:
- Stereotactic ablative radiotherapy provided durable local control (93%) with minimal toxicity in patients with oligoprogressive metastatic renal cell carcinoma, enabling deferral of systemic therapy escalation.
- Patients with fewer progressive lesions (< 2) derived the greatest benefit, while increasing lesion number was associated with significantly shorter modified progression-free survival.
- A non-significant signal toward improved outcomes was observed when stereotactic ablative radiotherapy was delivered concurrently with immunotherapy, supporting further prospective investigation.
Lucian Zhao, MD, UT Southwestern Medical Center, discusses outcomes from a large retrospective analysis evaluating stereotactic ablative radiotherapy in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Results demonstrated that stereotactic ablative radiotherapy achieved high local control while delaying the need for systemic therapy escalation, with outcomes strongly influenced by the number of progressive lesions at treatment. These findings help refine patient selection and support stereotactic ablative radiotherapy as a patient-centered strategy in oligoprogressive metastatic renal cell carcinoma.
These results were presented at the 2026 ACRO Radiation Oncology Summit in Orlando, Florida.
Source:
Zhao L. Stereotactic ablative radiotherapy for oligoprogressive metastatic RCC: Predictors of prolonged systemic therapy benefit. Presented at the 2026 ACRO Radiation Oncology Summit. February 4 - 7, 2026. Orlando, Florida. Abstract 1612
